Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Heidelberg, Germany, May 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
United States: +1 720-543-0214
Germany: +49 (0)89 20303 5709
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
